

# Ken Herrmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7019186/publications.pdf>

Version: 2024-02-01

216  
papers

10,648  
citations

44069

48  
h-index

40979

93  
g-index

220  
all docs

220  
docs citations

220  
times ranked

7809  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lutetium-177â€“PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1091-1103.	27.0	1,042
2	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024.	6.4	589
3	Assessment of <sup>68</sup> Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	7.1	493
4	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 469-478.	5.0	372
5	EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	6.4	265
6	Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 66-74.	5.0	228
7	<sup>68</sup> Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018, 59, 230-237.	5.0	226
8	First-in-Human Experience of CXCR4-Directed Endoradiotherapy with <sup>177</sup> Lu- and <sup>90</sup> Y-Labeled Pentixafer in Advanced-Stage Multiple Myeloma with Extensive Intra- and Extramedullary Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 248-251.	5.0	201
9	PET/CT with 11C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 55-69.	6.4	200
10	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
11	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638.	6.4	188
12	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	5.0	165
13	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	5.0	163
14	<sup>177</sup> Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	5.0	159
15	The Impact of Somatostatin Receptorâ€“Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 756-761.	5.0	158
16	<sup>18</sup> F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 420-430.	5.0	156
17	Radiation Dosimetry for <sup>177</sup> Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2017, 58, 445-450.	5.0	144
18	[ <sup>68</sup> Ga]Pentixafer-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [ <sup>18</sup> F]FDG and laboratory values. <i>Theranostics</i> , 2017, 7, 205-212.	10.0	138

#	ARTICLE	IF	CITATIONS
19	Diagnostic Accuracy of <sup>68</sup> Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. <i>JAMA Oncology</i> , 2021, 7, 1635.	7.1	138
20	Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 855-861.	5.0	122
21	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	2.8	120
22	Nomograms to predict outcomes after <sup>177</sup> Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	10.7	120
23	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 469-476.	6.4	119
24	CXCR4 Ligands: The Next Big Hit?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 77S-82S.	5.0	118
25	<sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	5.0	111
26	Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe <sup>68</sup> Ga-Pentixafor. <i>Journal of Nuclear Medicine</i> , 2015, 56, 410-416.	5.0	108
27	<sup>18</sup> F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1684-1689.	5.0	94
28	<sup>68</sup> Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma. <i>Theranostics</i> , 2016, 6, 428-434.	10.0	91
29	Comparison of the Amino Acid Tracers <sup>18</sup> F-FET and <sup>18</sup> F-DOPA in High-Grade Glioma Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1611-1616.	5.0	90
30	Potential Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1714-1721.	5.0	81
31	Proposal for Systemic-Therapy Response-Assessment Criteria at the Time of PSMA PET/CT Imaging: The PSMA PET Progression Criteria. <i>Journal of Nuclear Medicine</i> , 2020, 61, 678-682.	5.0	81
32	The predictive value of metabolic response to preoperative radiochemotherapy in locally advanced rectal cancer measured by PET/CT. <i>International Journal of Colorectal Disease</i> , 2009, 24, 191-200.	2.2	79
33	Impact of <sup>68</sup> Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy. <i>EJNMMI Research</i> , 2016, 6, 78.	2.5	78
34	PET/CT in Oncology: Current Status and Perspectives. <i>Current Radiology Reports</i> , 2013, 1, 177-190.	1.4	77
35	Current Concepts in <sup>68</sup> Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1718-1726.	5.0	76
36	Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving <sup>177</sup> Lu-PSMA-617 Radioligand Therapy. <i>Theranostics</i> , 2020, 10, 7812-7820.	10.0	75

#	ARTICLE	IF	CITATIONS
37	Impact of <sup>68</sup> Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	5.0	74
38	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1200-1210.	6.4	72
39	Comparison of <sup>68</sup> Ga-PSMA-11 and <sup>18</sup> F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. <i>Journal of Nuclear Medicine</i> , 2018, 59, 789-794.	5.0	68
40	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 9-15.	6.4	67
41	Evaluation of <sup>68</sup> Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with <sup>68</sup> Ga-DOTATOC PET/CT. <i>European Radiology</i> , 2017, 27, 4091-4099.	4.5	66
42	Nuclear Medicine Operations in the Times of COVID-19: Strategies, Precautions, and Experiences. <i>Journal of Nuclear Medicine</i> , 2020, 61, 626-629.	5.0	65
43	Initial clinical experience with <sup>90</sup> Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262468.	5.0	64
44	EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 67-72.	6.4	62
45	MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, e441-e463.	2.6	61
46	Impact of <sup>68</sup> Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective. <i>Journal of Nuclear Medicine</i> , 2015, 56, 70-75.	5.0	60
47	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. <i>EJNMMI Research</i> , 2018, 8, 96.	2.5	58
48	PET/MRI Versus PET/CT for Whole-Body Staging: Results from a Single-Center Observational Study on 1,003 Sequential Examinations. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1131-1136.	5.0	57
49	Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1278-1283.	5.0	51
50	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , The, 2020, 21, e431-e443.	10.7	51
51	Comparison of <sup>18</sup> F-FDG PET/MRI and MRI for pre-therapeutic tumor staging of patients with primary cancer of the uterine cervix. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 67-76.	6.4	49
52	Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 59S-62S.	5.0	45
53	Safety and Efficacy of <sup>90</sup> Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	7.0	45
54	Prospective comparison of <sup>18</sup> F-FDG PET/MRI and <sup>18</sup> F-FDG PET/CT for thoracic staging of non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 437-445.	6.4	44

#	ARTICLE	IF	CITATIONS
55	Integrated 18Fâ€“FDG PET/MRI compared to MRI alone for identification of local recurrences of soft tissue sarcomas: a comparison trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1823-1831.	6.4	43
56	PSMA ligands in prostate cancer â€“ Probe optimization and theranostic applications. Methods, 2017, 130, 42-50.	3.8	43
57	Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. European Radiology, 2021, 31, 8714-8724.	4.5	43
58	Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2122-2130.	6.4	42
59	Nuclear medicine and molecular imaging advances in the 21st century. British Journal of Radiology, 2020, 93, 20200095.	2.2	42
60	Tumor Sink Effect in <sup>68</sup> Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	5.0	42
61	Hybrid total-body pet scannersâ€”current status and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 445-459.	6.4	42
62	Comparison of 18Fâ€“FDG PET/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 622-629.	6.4	41
63	The salivary glands as a dose limiting organ of PSMA- targeted radionuclide therapy: A review of the lessons learnt so far. Nuclear Medicine and Biology, 2021, 98-99, 30-39.	0.6	40
64	Joint Imaging Platform for Federated Clinical Data Analytics. JCO Clinical Cancer Informatics, 2020, 4, 1027-1038.	2.1	39
65	Efficacy and Safety of 177Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. European Urology, 2020, 78, 148-154.	1.9	39
66	<sup>68</sup> Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2021, 62, 1235-1241.	5.0	39
67	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1177-1188.	3.1	38
68	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. BMC Cancer, 2020, 20, 326.	2.6	38
69	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 4271-4281.	6.4	38
70	In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CT. Acta Biomaterialia, 2020, 109, 244-253.	8.3	37
71	Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with <sup>177</sup> Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. Journal of Nuclear Medicine, 2021, 62, 1440-1446.	5.0	37
72	Evaluation of Prostate Cancer with <sup>11</sup> C-Acetate PET/CT. Journal of Nuclear Medicine, 2016, 57, 30S-37S.	5.0	36

#	ARTICLE	IF	CITATIONS
73	Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1S-2S.	5.0	36
74	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. <i>Journal of Nuclear Medicine</i> , 2016, 57, 2016-2021.	5.0	35
75	Establishing <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1786-1792.	5.0	35
76	Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization. <i>Journal of Clinical Medicine</i> , 2020, 9, 56.	2.4	35
77	Whole-body staging of female patients with recurrent pelvic malignancies: Ultra-fast 18F-FDG PET/MRI compared to 18F-FDG PET/CT and CT. <i>PLoS ONE</i> , 2017, 12, e0172553.	2.5	34
78	Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding. <i>Cancers</i> , 2021, 13, 2928.	3.7	34
79	18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine. <i>PLoS ONE</i> , 2017, 12, e0180349.	2.5	33
80	Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1162-1167.	5.0	32
81	Theranostics in Boron Neutron Capture Therapy. <i>Life</i> , 2021, 11, 330.	2.4	32
82	Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 992-1001.	6.4	32
83	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	6.4	30
84	A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3340-3352.	6.4	30
85	Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results. <i>Clinical Imaging</i> , 2018, 49, 163-168.	1.5	29
86	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162.	5.4	29
87	18F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. <i>PLoS ONE</i> , 2020, 15, e0227906.	2.5	29
88	Local and whole-body staging in patients with primary breast cancer: a comparison of one-step to two-step staging utilizing 18F-FDG-PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2328-2337.	6.4	28
89	Comparison of the clinical performance of upper abdominal PET/DCE-MRI with and without concurrent respiratory motion correction (MoCo). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2147-2154.	6.4	28
90	Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. <i>Radiology</i> , 2020, 296, 143-151.	7.3	28

#	ARTICLE	IF	CITATIONS
91	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. <i>Journal of Nuclear Medicine</i> , 2022, ,jnumed.121.263072.	5.0	28
92	Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study. <i>Clinical Cancer Research</i> , 2022, 28, 4194-4202.	7.0	28
93	Comparison of Different SUV-Based Methods for Response Prediction to Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer by FDG-PET and MRI. <i>Molecular Imaging and Biology</i> , 2011, 13, 1011-1019.	2.6	27
94	<sup>68</sup> Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 307-311.	5.0	27
95	Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. <i>Nuclear Medicine and Biology</i> , 2018, 61, 36-44.	0.6	26
96	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7431.	4.1	25
97	Most of the Intended Management Changes After <sup>68</sup> Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796.	5.0	24
98	Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 577-584.	5.0	24
99	Imaging Inflammation with Positron Emission Tomography. <i>Biomedicines</i> , 2021, 9, 212.	3.2	24
100	Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4028-4041.	6.4	24
101	Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1386-1406.	6.4	24
102	Prospective evaluation of whole-body MRI and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2816-2825.	6.4	23
103	Just another "Clever Hans"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3141-3150.	6.4	23
104	In Vivo Targeting of CXCR4 "New Horizons. <i>Cancers</i> , 2021, 13, 5920.	3.7	23
105	Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1742-1750.	6.4	22
106	Assessment of Ileocolonic Inflammation in Crohn's Disease: Which Surrogate Marker Is Better? MaRIA, Clermont, or PET/MR Index? Initial Results of a Feasibility Trial. <i>Journal of Nuclear Medicine</i> , 2019, 60, 851-857.	5.0	22
107	Impact of COVID-19 on Nuclear Medicine in Germany, Austria and Switzerland: An International Survey in April 2020. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 294-299.	0.7	22
108	Detection Threshold and Reproducibility of <sup>68</sup> Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1392-1397.	5.0	21

#	ARTICLE	IF	CITATIONS
109	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL&gt;60 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3550-3559.	6.4	21
110	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 88-91.	5.0	21
111	The role of <sup>124</sup> I PET/CT lesion dosimetry in differentiated thyroid cancer. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 235-252.	0.7	20
112	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 76-80.	5.0	20
113	Multiparametric <sup>18</sup> F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Cancers</i> , 2022, 14, 1727.	3.7	20
114	Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2300-2309.	6.4	20
115	EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [ <sup>177</sup> Lu]Lu-PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2022, 5, 530-536.	5.4	20
116	[ <sup>18</sup> F]FDG PET/MR enterography for the assessment of inflammatory activity in Crohn's disease: comparison of different MRI and PET parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1382-1393.	6.4	19
117	<sup>18</sup> F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1537-1542.	5.0	19
118	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1037-1042.	5.0	19
119	Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 170-183.	17.8	18
120	Dual-phase hybrid <sup>18</sup> F-fluoride Positron emission tomography/MRI in ankylosing spondylitis: Investigating the link between MRI bone changes, regional hyperaemia and increased osteoblastic activity. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 313-319.	1.8	18
121	Impact of <sup>18</sup> F-FDG PET/MR on therapeutic management in high risk primary breast cancer patients – A prospective evaluation of staging algorithms. <i>European Journal of Radiology</i> , 2020, 128, 108975.	2.6	18
122	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 396-398.	5.0	18
123	Clinical Use of PET/MR in Oncology: An Update. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 356-364.	4.6	18
124	Human Biodistribution and Radiation Dosimetry of <sup>18</sup> F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway. <i>Journal of Nuclear Medicine</i> , 2017, 58, 374-378.	5.0	17
125	Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 279-287.	3.1	17
126	<sup>18</sup> F-FDG PET/MRI in patients suffering from lymphoma: how much MRI information is really needed?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1005-1013.	6.4	16



#	ARTICLE	IF	CITATIONS
127	Diagnostic accuracy of 18F-FDG PET/CT and MR imaging in patients with adenoid cystic carcinoma. <i>BMC Cancer</i> , 2017, 17, 887.	2.6	16
128	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 363-369.	1.1	16
129	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678.	5.0	16
130	Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. <i>BMC Cancer</i> , 2021, 21, 62.	2.6	16
131	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	5.4	16
132	PSMA PET for the Assessment of Metastatic Hormone-Sensitive Prostate Cancer Volume of Disease. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1747-1750.	5.0	16
133	Quantitative performance of 124I PET/MR of neck lesions in thyroid cancer patients using 124I PET/CT as reference. <i>EJNMMI Physics</i> , 2018, 5, 13.	2.7	14
134	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	2.6	14
135	Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup> Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	5.0	14
136	Bone Metastases Are Measurable: The Role of Whole-Body MRI and Positron Emission Tomography. <i>Frontiers in Oncology</i> , 2021, 11, 772530.	2.8	14
137	PET Tracers in Musculoskeletal Disease beyond FDG. <i>Seminars in Musculoskeletal Radiology</i> , 2014, 18, 123-132.	0.7	13
138	68 Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block? Early or Too Early to Draw Conclusions?. <i>European Urology</i> , 2016, 70, 938-940.	1.9	13
139	Radiomics Analysis of Multiparametric PET/MRI for N- and M-Staging in Patients with Primary Cervical Cancer. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 754-763.	1.3	13
140	Changes in the global impact of COVID-19 on nuclear medicine departments during 2020: an international follow-up survey. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4318-4330.	6.4	13
141	Perceived Misinterpretation Rates in Oncologic <sup>18</sup> F-FDG PET/CT Studies: A Survey of Referring Physicians. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1925-1929.	5.0	12
142	Cardiac PET/MRI: Current Clinical Status and Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 260-269.	4.6	12
143	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. <i>European Journal of Cancer</i> , 2021, 144, 200-214.	2.8	12
144	18F-FDG PET-MR enterography in predicting histological active disease using the Nancy index in ulcerative colitis: a randomized controlled trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 768-777.	6.4	11

#	ARTICLE	IF	CITATIONS
145	Machine learning-based differentiation between multiple sclerosis and glioma WHO II <sup>o</sup> -IV <sup>o</sup> using O-(2-[ <sup>18</sup> F] fluoroethyl)-L-tyrosine positron emission tomography. <i>Journal of Neuro-Oncology</i> , 2021, 152, 325-332.	2.9	11
146	Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. <i>EJNMMI Physics</i> , 2021, 8, 14.	2.7	11
147	Impact of EBUS-TBNA in addition to [ <sup>18</sup> F]FDG-PET/CT imaging on target volume definition for radiochemotherapy in stage III NSCLC. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2894-2903.	6.4	11
148	Nuclear medicine theranostics comes of age. <i>Lancet Oncology</i> , The, 2021, 22, 1497-1498.	10.7	11
149	Prospective comparison of CT and <sup>18</sup> F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results. <i>PLoS ONE</i> , 2021, 16, e0260804.	2.5	11
150	Virtual Biopsy: Just an AI Software or a Medical Procedure?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 511-513.	5.0	11
151	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. <i>Journal of Nuclear Medicine</i> , 2019, 60, 7-8.	5.0	10
152	Comparison of <sup>18</sup> F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. <i>British Journal of Radiology</i> , 2020, 93, 20200167.	2.2	10
153	Appropriate Use Criteria for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer After Definitive Primary Treatment. <i>Journal of Nuclear Medicine</i> , 2020, 61, 552-562.	5.0	10
154	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 191-194.	5.0	10
155	Evaluation of [ <sup>68</sup> Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. <i>EJNMMI Research</i> , 2021, 11, 21.	2.5	10
156	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 101-111.	0.6	10
157	A Role of PET/MR in Breast Cancer?. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 611-618.	4.6	10
158	Driving the Future of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1S-2S.	5.0	9
159	Molecular Imaging for Primary Staging of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 271-279.	4.6	9
160	<sup>18</sup> F-FDG PET/MR versus MR Alone in Whole-Body Primary Staging and Restaging of Patients with Rectal Cancer: What Is the Benefit of PET?. <i>Journal of Clinical Medicine</i> , 2020, 9, 3163.	2.4	9
161	Evaluation of improved attenuation correction in whole-body PET/MR on patients with bone metastasis using various radiotracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2269-2279.	6.4	9
162	Evaluation of <sup>18</sup> F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. <i>Journal of Nuclear Medicine</i> , 2021, 62, 348-353.	5.0	9

#	ARTICLE	IF	CITATIONS
163	FDG-PET/CT Variants and Pitfalls in Haematological Malignancies. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 554-571.	4.6	9
164	Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1439-1447.	6.4	8
165	Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 67, .	0.7	8
166	Thymic hyperplasia after mRNA based Covid-19 vaccination. <i>Radiology Case Reports</i> , 2021, 16, 3744-3745.	0.6	8
167	Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. <i>Endocrine</i> , 2022, 75, 293-302.	2.3	8
168	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography May Exclude Malignancy in Sonographically Suspicious and Scintigraphically Hypofunctional Thyroid Nodules and Reduce Unnecessary Thyroid Surgeries. <i>Thyroid</i> , 2017, 27, 1300-1306.	4.5	7
169	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [18F]FDG PET/CT and [18F]FDG PET/MRI. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 183-191.	1.0	7
170	Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC. <i>Cancers</i> , 2021, 13, 1728.	3.7	7
171	Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas. <i>Cancers</i> , 2021, 13, 2753.	3.7	7
172	Individualized treatment of differentiated thyroid cancer: The value of surgery in combination with radioiodine imaging and therapy – A German position paper from Surgery and Nuclear Medicine. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, .	0.7	7
173	Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors. <i>Immunotherapy</i> , 2022, 14, 927-944.	2.0	7
174	PET imaging in prostate cancer, future trends: PSMA ligands. <i>Clinical and Translational Imaging</i> , 2016, 4, 467-472.	2.1	6
175	Molecular Imaging and Therapy of Colorectal and Anal Cancer. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 465-470.	4.6	6
176	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	5.0	6
177	An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1522-1537.	6.4	6
178	Repeatability of 68Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262528.	5.0	6
179	Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and 18F-FDG PET/CT for radiotherapy target volume definition. <i>Radiation Oncology</i> , 2021, 16, 176.	2.7	6
180	Effects of Anti-Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine. <i>Arthritis and Rheumatology</i> , 2022, 74, 1497-1505.	5.6	6

#	ARTICLE	IF	CITATIONS
181	Pretherapeutic <sup>124</sup> I dosimetry reliably predicts intratherapeutic blood kinetics of <sup>131</sup> I in patients with differentiated thyroid carcinoma receiving high therapeutic activities. <i>Nuclear Medicine Communications</i> , 2018, 39, 457-464.	1.1	5
182	Diagnostic Performance of Simultaneous [ <sup>18</sup> F]-FDG PET/MR for Assessing Endoscopically Active Inflammation in Patients with Ulcerative Colitis: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2474.	2.4	5
183	Comparison of acceptance of PET/MR enterography and ileocolonoscopy in patients with inflammatory bowel diseases. <i>Clinical Imaging</i> , 2020, 64, 11-17.	1.5	5
184	Nuclear Medicine beyond VISION. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262441.	5.0	5
185	Correlation between contrast enhancement, standardized uptake value (SUV), and diffusion restriction (ADC) with tumor grading in patients with therapy-naïve neuroendocrine neoplasms using hybrid <sup>68</sup> Ga-DOTATOC PET/MRI. <i>European Journal of Radiology</i> , 2021, 137, 109588.	2.6	5
186	Prognostic Value of Postinduction Chemotherapy Volumetric PET/CT Parameters for Stage IIIA or IIIB Non-Small Cell Lung Cancer Patients Receiving Definitive Chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1684-1691.	5.0	5
187	First experiences with dynamic renal [ <sup>68</sup> Ga]Ga-DOTA-PET/CT: a comparison to renal scintigraphy and compartmental modelling to non-invasively estimate the glomerular filtration rate. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3373-3386.	6.4	5
188	Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1836-1843.	5.0	5
189	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 816-823.	4.6	5
190	Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation. <i>Lung Cancer</i> , 2020, 139, 165-168.	2.0	4
191	Correlation of the apparent diffusion coefficient (ADC) and standardized uptake values (SUV) with overall survival in patients with primary non-small cell lung cancer (NSCLC) using <sup>18</sup> F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2021, 134, 109422.	2.6	4
192	EANM Focus 3: The International Conference on Molecular Imaging and Theranostics in Neuroendocrine Tumours—the consensus in a nutshell. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1276-1277.	6.4	4
193	Comparison of pre- and post-contrast-enhanced attenuation correction using a CAIPI-accelerated T1-weighted Dixon 3D-VIBE sequence in <sup>68</sup> Ga-DOTATOC PET/MRI. <i>European Journal of Radiology</i> , 2021, 139, 109691.	2.6	4
194	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls. <i>Translational Andrology and Urology</i> , 2021, 10, 3972-3985.	1.4	4
195	Imaging the Inflammatory Response in Checkpoint Inhibition Myocarditis. <i>Journal of Nuclear Medicine</i> , 2022, 63, 14-16.	5.0	4
196	Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of <sup>2</sup> -[ <sup>18</sup> F]FDG-PET/CT external beam radiation treatment planning in lung cancer. <i>Radiotherapy and Oncology</i> , 2022, 168, 37-39.	0.6	4
197	Insights into immunometabolism: A dataset correlating the <sup>18</sup> F-FDG PET/CT maximum standard uptake value of the primary tumor with the CCL18 serum level in non-small cell lung cancer. <i>Data in Brief</i> , 2021, 35, 106859.	1.0	3
198	<sup>18</sup> F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 199-204.	5.0	3

#	ARTICLE	IF	CITATIONS
199	â€œCOVID-19 Pandemic as stimulator to Re-Establish Nuclear Medicine as Clinical Specialtyâ€•based on a report of Prof. Dr. Ignasi Carrio. Nuklearmedizin - NuclearMedicine, 2020, 59, 405-408.	0.7	3
200	Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology. International Journal of Molecular Sciences, 2022, 23, 3802.	4.1	3
201	2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2668-2669.	6.4	2
202	Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.. Journal of Clinical Oncology, 2021, 39, 5066-5066.	1.6	2
203	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. EJNMMI Research, 2021, 11, 68.	2.5	2
204	COVID-19 Pandemic: What Have We Learned and What to Expect in the Future?. Seminars in Nuclear Medicine, 2022, 52, 86-89.	4.6	2
205	Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 520-521.	1.9	2
206	Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma. Cancer Imaging, 2022, 22, 11.	2.8	2
207	Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRI. EJNMMI Physics, 2022, 9, 11.	2.7	2
208	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. Molecular Imaging and Biology, 2022, , 1.	2.6	2
209	Administration Routes for SSTR/PSMA- and FAP-Directed Theranostic Radioligands in Mice. Journal of Nuclear Medicine, 2022, 63, 1357-1363.	5.0	1
210	Atypical bilateral ventilation/perfusion mismatches in an asymptomatic patient suffering from metastatic thyroid cancer. European Journal of Hybrid Imaging, 2021, 5, 25.	1.5	1
211	Therapy Monitoring with Fluorine-18 FDG-PET and Fluorine-18 FDG-PET/CT. PET Clinics, 2008, 3, 217-226.	3.0	0
212	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. European Urology, 2017, 71, 934-935.	1.9	0
213	Current and Emerging Applications. , 2018, , 1-8.		0
214	Is there a connection between immunohistochemical markers and grading of lung cancer with apparent diffusion coefficient (ADC) and standardised uptake values (SUV) of hybrid 18Fâ€•FDGâ€•PET/MRI?. Journal of Medical Imaging and Radiation Oncology, 2020, 64, 779-786.	1.8	0
215	Re: Prostate-specific Membrane Antigen PET-CT in Patients with High-risk Prostate Cancer Before Curative-intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multi-centre Study. European Urology, 2020, 78, 470-471.	1.9	0
216	FDG-PET avidity as a prognostic biomarker for overall survival in renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, e16564-e16564.	1.6	0